scPharmaceuticals Inc. (SCPH) Research

scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients. The company's pipeline also encompasses scCeftriaxone, an antibiotic aimed at treating infections caused by both gram-positive and gram-negative bacteria, as well as the scCarbapenem program, another antibiotic designed for gram-negative bacterial infections. Additionally, scPharmaceuticals has entered into a collaboration agreement with West Pharmaceutical Services, Inc. for the advancement of a single-use SmartDose device. Founded in 2013, the company's main operations are based in Burlington, Massachusetts.

Market snapshot

Symbol
SCPH
Price
$5.67
Day change
0.00%
Market cap
$302.2M
P/E ratio
-5.38x
52-week range
1.94-6.28
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$8.12

Peer companies

  • Checkpoint Therapeutics, Inc. (CKPT)
  • Climb Bio, Inc. (CLYM)
  • Inozyme Pharma, Inc. (INZY)
  • Standard BioTools Inc. (LAB)
  • Orchard Therapeutics plc (ORTX)
  • Acelyrin, Inc. (SLRN)
  • Spectrum Pharmaceuticals, Inc. (SPPI)
  • Third Harmonic Bio, Inc. (THRD)

Recent insider activity

  • SCHAEFFER LEONARD D — U-Tender (43104 shares) on 2025-10-07
  • SCHAEFFER LEONARD D — D-Return (19750 shares) on 2025-10-07
  • SCHAEFFER LEONARD D — D-Return (30000 shares) on 2025-10-07
  • SCHAEFFER LEONARD D — D-Return (16300 shares) on 2025-10-07
  • VEITINGER KLAUS R DR — D-Return (30000 shares) on 2025-10-07

Open scPharmaceuticals Inc. (SCPH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.